The Japanese Government’s IP Strategic Headquarters announced plans to revise the patent examination standards for medical inventions of known drug compounds. The new standard will grant patent protection for new and inventive dosage regimens and modes of administration as a “product-related invention” provided the claimed medicament has remarkable effects beyond that which is expected by a person skilled in the art. The new examination standard will go into effect as early as the end of this year.
Since 2005, Japan has allowed new medicinal use claims of a known pharmaceutical ingredient to be a patentable subject matter. However, this will be the first time novelty is conferred on optimization of known medicines. Talks are also underway for methods for medical treatment claims (claims pertaining to surgery and other therapeutic treatment of the human body) to be patentable. Those in the pharmaceutical industry should see this change as a very positive step towards other changes to come relating to patents for medical inventions.
The Japan IP Strategic Headquarter’s report entitled “The Current State of Patent Protection in Advanced Medicine” is here. (via Keisen Associates)
Related posts:
- Registration of Provisional Non-Exclusive Licenses In Japan Patent Office Now, provisional exclusive and/or non-exclusive licenses can be registered at...
- EPO: Dosage Regime Patentable Even If It is The Only Novel Feature The therapeutic use of that substance cannot be patented because...
- Japan Patent Office Offers Economic Stimulus Package The Japan Patent Office has just announced a new policy...
- EPO Enlarged Board of Appeal: Method Patentable By Disclaiming Unpatentable Step The EPO Enlarged Board of Appeal handed down its decision...
- Innovation Patents: Australian Court Rules on Innovative Step Innovation patents are second tier patents similar to utility models,...
Related posts brought to you by Yet Another Related Posts Plugin.
